CSL – Morgan Stanley rates the stock as Equal-weight

Morgan Stanley feels the tempo of recovery for plasma collection is at risk after CSL lost its court challenge against the US Centre for Border Protection.

Only 16 of 304 collection centres are near the US/Mexican border, though they collect more than average, notes the broker. The Equal-weight rating and target price of $280.00 are retained. Industry view: In line.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.


Target price is $280.00.Current Price is $296.29. Difference: ($16.29) – (brackets indicate current price is over target). If CSL meets the Morgan Stanley target it will return approximately -6% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →